Pricing Log in Create free account

Denali Therapeutics Inc. (DNLI) vs Dyne Therapeutics, Inc. (DYN)

Denali Therapeutics Inc. and Dyne Therapeutics, Inc. are both Biotechnology companies. Denali Therapeutics Inc. and Dyne Therapeutics, Inc. are of similar size ($2.9B and $2.9B). Dyne Therapeutics, Inc. has the higher net margin (0.00% vs −171.1%) and the lower return on invested capital (−1,956.3% vs −260.5%). Across the 14 metrics below, Denali Therapeutics Inc. leads on 8 and Dyne Therapeutics, Inc. on 6.

Valuation

Metric DNLI DYN Biotechnology median
P/E n/m n/m 8.50
P/S 11.00 n/m 9.71
P/B 3.94 3.36 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 8.64 n/m 9.21
Earnings yield (16.17%) (23.37%) (33.15%)
Free cash flow yield (13.30%) (20.38%) (25.50%)

Profitability

Metric DNLI DYN Biotechnology median
Gross margin 99.97% 0.00% 65.16%
Operating margin (181.51%) 0.00% 0.00%
Net margin (171.06%) 0.00% 0.00%
Free cash flow margin (146.31%) 0.00% 0.00%
Return on equity (54.93%) (81.57%) (56.36%)
Return on assets (44.01%) (60.29%) (48.04%)
Return on invested capital (260.54%) (1,956.27%) 0.00%

Growth

Metric DNLI DYN Biotechnology median
Revenue growth (TTM) 194.68% — 6.02%
EPS growth (last fiscal year) (15.56%) (2.97%) 30.26%
Revenue growth, 5-year CAGR 20.67% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DNLI DYN Biotechnology median
Debt to equity 0.01 0.30 0.00
Current ratio 8.37 12.02 4.72
Net debt to EBITDA 1.56 2.05 0.96

Dividend

Metric DNLI DYN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric DNLI DYN Biotechnology median
Market cap 2.93b 2.86b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack